198 related articles for article (PubMed ID: 24505235)
1. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance.
LeBeau AM; Sevillano N; King ML; Duriseti S; Murphy ST; Craik CS; Murphy LL; VanBrocklin HF
Theranostics; 2014; 4(3):267-79. PubMed ID: 24505235
[TBL] [Abstract][Full Text] [Related]
2. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer.
LeBeau AM; Duriseti S; Murphy ST; Pepin F; Hann B; Gray JW; VanBrocklin HF; Craik CS
Cancer Res; 2013 Apr; 73(7):2070-81. PubMed ID: 23400595
[TBL] [Abstract][Full Text] [Related]
3. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
Miller-Kleinhenz J; Guo X; Qian W; Zhou H; Bozeman EN; Zhu L; Ji X; Wang YA; Styblo T; O'Regan R; Mao H; Yang L
Biomaterials; 2018 Jan; 152():47-62. PubMed ID: 29107218
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR).
Liu D; Overbey D; Watkinson L; Giblin MF
Bioconjug Chem; 2009 May; 20(5):888-94. PubMed ID: 19354275
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
6. uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection.
Yang L; Sajja HK; Cao Z; Qian W; Bender L; Marcus AI; Lipowska M; Wood WC; Wang YA
Theranostics; 2013; 4(1):106-18. PubMed ID: 24396518
[TBL] [Abstract][Full Text] [Related]
7. Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells.
Jo M; Eastman BM; Webb DL; Stoletov K; Klemke R; Gonias SL
Cancer Res; 2010 Nov; 70(21):8948-58. PubMed ID: 20940399
[TBL] [Abstract][Full Text] [Related]
8. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET.
Li ZB; Niu G; Wang H; He L; Yang L; Ploug M; Chen X
Clin Cancer Res; 2008 Aug; 14(15):4758-66. PubMed ID: 18676745
[TBL] [Abstract][Full Text] [Related]
9. Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.
Dutta S; Bandyopadhyay C; Bottero V; Veettil MV; Wilson L; Pins MR; Johnson KE; Warshall C; Chandran B
Mol Oncol; 2014 May; 8(3):483-507. PubMed ID: 24457100
[TBL] [Abstract][Full Text] [Related]
10. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion.
Persson M; Madsen J; Østergaard S; Jensen MM; Jørgensen JT; Juhl K; Lehmann C; Ploug M; Kjaer A
J Nucl Med; 2012 Jan; 53(1):138-45. PubMed ID: 22213823
[TBL] [Abstract][Full Text] [Related]
11. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
12. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
13. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
14. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
Moreau M; Mourah S; Dosquet C
Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
[TBL] [Abstract][Full Text] [Related]
15. Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion.
Khanna M; Wang F; Jo I; Knabe WE; Wilson SM; Li L; Bum-Erdene K; Li J; W Sledge G; Khanna R; Meroueh SO
ACS Chem Biol; 2011 Nov; 6(11):1232-43. PubMed ID: 21875078
[TBL] [Abstract][Full Text] [Related]
16. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Xing RH; Mazar A; Henkin J; Rabbani SA
Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
[TBL] [Abstract][Full Text] [Related]
17. DOT corrected fluorescence molecular tomography using targeted contrast agents for small animal tumor imaging.
Tan Y; Cao Z; Sajja HK; Lipowska M; Wang YA; Yang L; Jiang H
J Xray Sci Technol; 2013; 21(1):43-52. PubMed ID: 23507851
[TBL] [Abstract][Full Text] [Related]
18. Effects of ulinastatin and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERK.
Luo J; Sun X; Gao F; Zhao X; Zhong B; Wang H; Sun Z
J Exp Clin Cancer Res; 2011 Jul; 30(1):71. PubMed ID: 21798065
[TBL] [Abstract][Full Text] [Related]
19. IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts.
Kurbegovic S; Juhl K; Sørensen KK; Leth J; Willemoe GL; Christensen A; Adams Y; Jensen AR; von Buchwald C; Skjøth-Rasmussen J; Ploug M; Jensen KJ; Kjaer A
Theranostics; 2021; 11(15):7159-7174. PubMed ID: 34158842
[TBL] [Abstract][Full Text] [Related]
20. In vivo detection of urokinase-type plasminogen activator receptor (uPAR) expression in arterial atherogenesis using [
Khare HA; Døssing KBV; Ringgaard L; Christensen E; Urbak L; Sillesen H; Ripa RS; Binderup T; Pedersen SF; Kjaer A
Atherosclerosis; 2022 Jul; 352():103-111. PubMed ID: 35396143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
